BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

DBV Technologies and Bioprojet Enter Into Distribution Agreement For Diallertest(R) Milk


10/12/2009 2:38:34 PM

Paris, France – 12 October 2009 – DBV Technologies, a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced today that it has signed a distribution agreement with BIOPROJET pharma for DBV’s Cow’s Milk protein allergy diagnostic, Diallertest® Milk. Under the terms of the agreement, BIOPROJET Pharma will promote and distribute Diallertest® Milk in France.

BIOPROJET pharma, a French paediatric focused pharmaceutical company, markets a number of products in France including Tiorfan® ( a leading anti-diarrheal drug) Fanomer® (a nasal spray for children) and Fanolyte® (an oral rehydration solution). Since 2002, BIOPROJET Pharma has extended its distribution networks to include major European and overseas markets.

“We are extremely pleased to have signed this distribution deal with BIOPROJET Pharma,” said DBV Technologies Chairman and CEO Jean François Biry. “The agreement will enable wider access to a diagnostic for a condition that is very difficult to diagnose which is also the cause of significant pain and distress for infants.”

“Diallertest® Milk is a non-invasive, easy to use and pain free approach for the diagnosis of cow’s milk protein allergy. “It fits well with our existing product range and we look forward to working with DBV to make Diallertest® Milk more widely available throughout Europe”, commented BIOPROJET Pharma CEO Dr. Jeanne-Marie Lecomte.

DBV Technologies is currently working on the further development of its Diallertest® product range for the diagnosis of wheat, soya and dustmite allergies in children.

About DBV Technologies - www.dbv-technologies.com

DBV Technologies is a speciality pharma company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergy diagnosis and treatment. The Company is lead by CEO Jean-François Biry and was born out of the experience of Professor christophe Dupont, a paediatric GI from Assistance Publique-Hôpitaiux de Paris and Universiy Paris Descartes Doctor Pierre-Henri Benhamou, a paediatrician specialising in gastro-enterology, allergosis and nutrition, and Bertrand Dupont, a qualified engineer from the Arts et Métiers Institute. DBV Technologies’ lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.

DBV closed a €6million (EUR) Series B investment in January 2009 with new investor ALK-Abello, a leading worldwide immunotherapy company, and returning investor Sofinnova Partners.

DBV Technologies was founded in 2002 and is based in the Pépinière Paris Santé Cochin, in Paris’ 14th arrondissement.

About VIASKIN®

DBV Technologies’ globally patented VIASKIN® technology is a unique delivery system which retains active compounds on a carrier using electrostatic forces only. The delivery platform allows active compounds to be presented to the epidermis of the skin without breaking the blood-skin barrier. In not breaking the blood-skin barrier, DBV Technologies’ allergen diagnosis and specific immunotherapy treatments avoid inducing systemic shock – one of the most serious concerns associated with current desensitisation therapies.

DBV Technologies’ VIASKIN® technology is in development for the treatment of allergies through Epicutaneous Specific Immunotherapy (EPIT) and for the administration of vaccines. The company is currently seeking partnerships in these areas DBV Technologies’ lead product, Diallertest® Milk, utilises VIASKIN® technology and is on sale in France and other countries for the diagnosis of cow’s milk protein allergy.

To view a video of VIASKIN presenting active compounds to the skin without breaking the blood-skin barrier, please click on the link http://www.dbv-technologies.com/viaskin-technology/about.htm

About Diallertest® Milk

DBV Technologies’ lead product, Diallertest® Milk, is on sale in France and other countries for the diagnosis of cow’s milk protein allergy. Diallertest® Milk represents a revolution for paediatrics and was awarded an International prize for Technological Innovation by the Altran foundation in 2003.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES